GRAL Share Price Performance
GRAL Community Fair Values
- US$40.50FV19.0% undervalued intrinsic discount18.41%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative10users have followed this narrativeabout 1 month ago author updated this narrative
Recent GRAL News & Updates
No updates
GRAIL, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 12, 2025
- Earnings per share (EPS)
- -53.21
- Gross Margin
- -58.18%
- Net Profit Margin
- -1,464.53%
- Debt/Equity Ratio
- 0%
GRAIL, Inc. Competitors
About GRAL
- Founded
- 2015
- Employees
- 1000
- CEO
- WebsiteView website
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.7%
- 1 Year: 17.5%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. As for the longer term, the market has actually risen by 18% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading